Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953665 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Liraglutide in Parkinson's Disease
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02953665 is a Phase 2 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 63 participants.
The verdict
NCT02953665, a Phase 2 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
Interventions
- DRUG Placebo
- DRUG Liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953665
The ClinicalTrials.gov registry entry for NCT02953665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02953665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953665 about?
NCT02953665 is a clinical study titled "Safety and Efficacy of Liraglutide in Parkinson's Disease". The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
What is the current status of trial NCT02953665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2017-04-03. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT02953665?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG).
Who is sponsoring clinical trial NCT02953665?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.